Verastem: Novel Drugs Targeting Cancer Stem Cells

Progress Update and 2015 Outlook
Thursday, January 8 at 4:30 p.m. ET. Click Here for Webcast »

Verastem, Inc. (NASDAQ: VSTM) is a clinical-stage biopharmaceutical company focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells. Cancer stem cells are an underlying cause of tumor recurrence and metastasis. Verastem is developing small molecule inhibitors of signaling pathways that are critical to cancer stem cell survival and proliferation: FAK, PI3K/mTOR and Wnt.

 

 

ANNOUNCEMENTS

January 29, 2015
Verastem Announces Closing of $54 Million Public Offering of Common Stock and Exercise in Full of Underwriters’ Option to Purchase Additional Shares

January 22, 2015
Verastem Announces Pricing of Public Offering of Common Stock

January 20, 2015
Verastem Announces Proposed Public Offering of Common Stock

 

Cancer Stem Cells

The majority of cancer drugs, while killing the bulk of tumor cells, ultimately fail to induce durable clinical responses. A reason for this failure may be the presence of a minority of cells in the tumor called cancer stem cells which are resistant to existing cancer therapies.

Using our proprietary technology we are identifying and developing drugs that target and kill cancer stem cells.

Learn More »